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Abstract: In this study, we introduce and use Efﬁ  ciency Analysis to compare differences in the apparent internal and external 
consistency of competing normalization methods and tests for identifying differentially expressed genes. Using publicly 
available data, two lung adenocarcinoma datasets were analyzed using caGEDA (http://bioinformatics2.pitt.edu/GE2/GEDA.
html) to measure the degree of differential expression of genes existing between two populations. The datasets were ran-
domly split into at least two subsets, each analyzed for differentially expressed genes between the two sample groups, and 
the gene lists compared for overlapping genes. Efﬁ  ciency Analysis is an intuitive method that compares the differences in 
the percentage of overlap of genes from two or more data subsets, found by the same test over a range of testing methods. 
Tests that yield consistent gene lists across independently analyzed splits are preferred to those that yield less consistent 
inferences. For example, a method that exhibits 50% overlap in the 100 top genes from two studies should be preferred to 
a method that exhibits 5% overlap in the top 100 genes. The same procedure was performed using all available normaliza-
tion and transformation methods that are available through caGEDA. The ‘best’ test was then further evaluated using 
internal cross-validation to estimate generalizable sample classiﬁ  cation errors using a Naïve Bayes classiﬁ  cation algorithm. 
A novel test, termed D1 (a derivative of the J5 test) was found to be the most consistent, and to exhibit the lowest overall 
classiﬁ  cation error, and highest sensitivity and speciﬁ  city. The D1 test relaxes the assumption that few genes are differentially 
expressed. Efﬁ  ciency Analysis can be misleading if the tests exhibit a bias in any particular dimension (e.g. expression 
intensity); we therefore explored intensity-scaled and segmented J5 tests using data in which all genes are scaled to share 
the same intensity distribution range. Efﬁ  ciency Analysis correctly predicted the ‘best’ test and normalization method using 
the Beer dataset and also performed well with the Bhattacharjee dataset based on both efﬁ  ciency and classiﬁ  cation accuracy 
criteria.
Introduction
Cancer research has generated a rich and complex body of knowledge, revealing cancer to be a disease 
involving dynamic changes in the genome.
1 Research over the past decades has revealed a number of 
molecular, biochemical, and cellular traits shared by most and perhaps all types of human cancer.
2 
However, today there is a need to look at all cancers from different perspectives, using genomic
1,3 and 
proteomic
4,5 molecular techniques and try to achieve results in ways that never seemed possible.
6
Lung cancer remains the leading cause of cancer death in industrialized countries, claiming more 
than 150,000 lives annually in the US.
7 The overall 10-year survival rate is a staggering 8%–10%,
8 and 
it is currently impossible to identify the high-risk patients.
9 Today, lung carcinoma classiﬁ  cation is based 
on clinicopathology. The subclassiﬁ  cation of lung cancers is very challenging, and studies have shown 
that different pathologists have differed on subclassiﬁ  cation of the same carcinomas more than half of 
the time.
10 Determining metastasis of non-lung origin from lung adenocarcinomas is also difﬁ  cult.
11,12 
A broader basis of the molecular biology of lung carcinomas could help aid in prediction of outcome, 
choice of therapies, and identiﬁ  cation of new biomarkers.
13
Microarray technology has made it possible for researchers to search for molecular markers of most 
cancers.
14–20 A number of lung cancer studies have settled upon variable numbers in different sets of 
genes for successful prognostic classiﬁ  ers, including Xi et al.
21 (318 genes), Lu et al.
22 (64 genes), Sun 
et al.
23 (50 genes), Jiang et al.
24 (36 genes), Bianchi et al.
25 (10 genes), Chen et al.
26 (5 genes), and Lau 
et al.
27 (3 genes). The resulting classiﬁ  ers may be used in all areas of prediction such as detection, choice 390
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of therapy, metastasis, and survival outcomes. 
While many of these models may exhibit very good 
accuracy, none have been clinically imple-
mented.
By making their datasets publicly available, 
researchers provide opportunities for re-analysis 
of their data by others, including the opportunity 
for the comparison of a variety of distinct 
approaches to analysis. New methods of analysis 
can be developed and evaluated, hopefully leading 
to improvements in our understanding of the dif-
ferences in the performance of distinct methods. 
In this study, we have re-analyzed the publicly 
available lung adenocarcinoma datasets of Beer 
et al.
9 and Bhattacharjee et al.
13 (both extensively 
studied at CAMDA 2003 conference; http://www.
camda.duke.edu/camda03.html). Additionally, 
Efﬁ  ciency Analysis was also performed using data 
from the Guo et al.
28 rat toxicogenomic study data 
(MAQC Project). We will not try to duplicate or 
scrutinize their results, but rather use their data to 
assess a variety of analysis methods.
It is important to mention that the word ‘efﬁ  -
ciency’ is used in statistics for describing the rela-
tive size of the variance of an estimator to a fully 
efﬁ  cient estimator like the maximum likelihood. 
We introduce the concept of an empirical method 
to study efﬁ  ciency through the consistency of 
statistical inferences made with any estimator. The 
term here is used in a slightly more generic manner 
as the relative internal consistency at a particular 
sample size. Methods that show higher internal 
consistency at a small N have more apparent power, 
and are therefore more efficient because they 
require lower N to achieve the same or higher 
observed degree of internal consistency compared 
to methods that require larger N.
Materials and Methods
Data retrieval
Portions of both datasets, Beer, et al. and 
Bhattacharjee, et al. are already available on the 
caGEDA website (http://bioinformatics2.pitt.edu/
GE2/GEDA.html),
29 and the data can also be 
obtained by links from the subsequent journal 
articles.
9,13 Each dataset contained 5377 genes. The 
Beer dataset used contains data from 69 neoplastic 
lung adenocarcinoma samples and 17 non-
neoplastic samples. The Bhattacharjee dataset used 
contained 52 neoplastic and 17 non-neoplastic 
samples. The datasets used either the Affymetrix 
HUGeneFL or the HG_U95Av2 microarray chip 
platforms, respectively. Probe sets were merged 
by joining Unigene cluster ID’s.
Data and statistical analysis
All test, normalization, and transformation analyses 
were performed using caGEDA, a freely available 
informatics tool. The datasets were analyzed for 
differentially expressed genes (DE genes). 
Efﬁ  ciency Analysis was performed followed by 
Random Resampling Validation (RRV) using a 
Naïve Bayes Classifier, and PACE Analysis 
(all described below).
Efﬁ  ciency analysis
Efﬁ  ciency Analysis is a new method for comparing 
the apparent internal, or external, consistency in 
the list of genes found by competing methods for 
feature selection. In its current application, Efﬁ  -
ciency Analysis is implemented as a method that 
compares the differences in the percentage of 
overlap of two or more methods found at the same 
numerical index (number) of overlapping genes, in 
randomly split datasets. For example, a method that 
exhibits 50% overlap in the 100 top genes from 
two studies should be preferred to a method that 
exhibits 5% overlap in the top 100 genes. For any 
test (using the same starting list), the lists overlap 
is 100% when all genes are included (no feature 
selection), assuming the same chip content. As one 
applies increasing stringency to the criterion for 
feature selection to two datasets, the number of 
genes that are retained decreases, and therefore the 
number that overlap between the two lists decreases. 
For any method that is less than perfectly consis-
tent, the proportion of overlap decays as well 
(as the number of genes approaches zero). Methods 
exhibiting the highest percent overlap, at a given 
threshold of a ﬁ  lter or test, (which deﬁ  nes that 
number of genes in the observer overlap), are con-
sidered the most efﬁ  cient. For internal Efﬁ  ciency 
Analysis, a dataset of  N samples is split into n non-
overlapping sets, each with N/n samples. For 
external Efﬁ  ciency Analysis, two (or more) inde-
pendent datasets are generated that address the 
same biological or clinical question. In either case 
(internal or external), a given test T (t-, F-, fold-
change, etc) is applied to all genes in each dataset 
separately. The threshold (cut-point) associated 
with signiﬁ  cance level is increased in a stepwise 391
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manner over the range of significance levels 
(thresholds) for the test in n datasets. The percent 
overlap (O) in the independently determined ranked 
gene lists is determined at each threshold value 
(O is the relative size of the area of the overlap to 
the non-overlap in a Venn diagram (Fig. 1). N1 and 
N2 are the number of genes found to be signiﬁ  cant 
at a given threshold value in dataset 1 and 2, respec-
tively, and N3 is the number of genes in the inter-
section of the datasets (size of overlap, then O = N3/ 
(N1 + N2 − N3). Plotting O VS. N3 creates an 
‘efﬁ  ciency curve’ for a given test (Fig. 2). For all 
values of N3M (the total number of genes), the 
test (t-, F-, fold-change, etc.) with the highest O at 
a given N3 is said to be the most efﬁ  cient. For any 
given test, the threshold associated with N3M 
associated with the highest O is speculated to be 
optimal for that test. This approach does not 
attempt to estimate the false discovery rate 
(FDR; expected ratio of false positives among the 
signiﬁ  cant results) but instead uses empirical con-
sistency to guide researchers in the selection of 
competing diverse methods. The curve also may 
point to a test-threshold that exhibits increased 
local efﬁ  ciency.
Initially, each dataset was split randomly into 
four representative groups; with each containing 
at least four normal samples and with one of the 
four groups containing five normals. Internal 
Efﬁ  ciency Analysis was performed within each 
dataset using the Efﬁ  ciency Analysis option in 
caGEDA (‘internal Efﬁ  ciency Analysis’). For all 
of the tests described in this paper, external Efﬁ  -
ciency Analysis was also performed using com-
pletely independent datasets (‘external Efﬁ  ciency 
Analysis’). External efficiency curves were 
generated by pasting the ranked gene lists, with 
their associated test scores, into the Overlap4 tool 
http://bioinformatics.pitt.edu/GE2/Overlap4.html 
with a step of 0.1. The ﬁ  nal gene list contains: 
1) percentage of overlap (O) at a given threshold, 
for a speciﬁ  ed number of genes (N3), and 2) for 
each selected gene, the percentage for degree of 
differential expression. As an independent check 
on the potential utility of the various gene lists, all 
tests were assessed for classiﬁ  cation error using 
internal cross-validation (RRV with a 70%–30% 
split, performed at 100 iterations) with a Naïve 
Bayes classiﬁ  er over the range of signiﬁ  cance level 
for each test.
Tests for differential expression
Lung cancer data
Detailed descriptions about the tests examined 
can be found on the caGEDA website (http://
bioinformatics2.pitt.edu/GE2/GEDA.html)
29 and 
some brief descriptions of  the threshold-based tests 
and normalization methods are described in 
Appendix A. For most tests, a threshold of 0 was 
used for all tests so that all genes were returned 
with a score. Random Feature Selection (RFS) used 
a threshold range that spanned from 0 to the total 
number of genes (5377 distinct genes) to produce 
an appropriate and comparable result. PPST
30 and 
SAM
31 are permutation tests and were performed 
as such using the following settings: PPST using 
100 permutations, threshold 1, and 1–99 quantiles; 
SAM using 100 permutations, δ of −1, and a δ’ of 0. 
The Segmented J5, described here for the ﬁ  rst time, 
used 100 percentiles and a threshold of 0 for analysis. 
Any missing values were estimated using the 
K-Nearest Neighbor method with 3 neighbors.
32 Non-
distinct gene values were averaged. For initial assess-
ment of the tests, no normalization/transformation 
method was used. For the normalizations/
transformations, the best performing test within 
the acceptable gene number range, D1, was used to 
find the best accompanying normalization/
transformation method.
Rat toxicogenomic data
Data were obtained from the MAQC Project 
website (http://www.fda.gov/nctr/science/centers/
toxicoinformatics/maqc/). Efﬁ  ciency Analysis was 
performed for the desired tests using caGEDA 
and parameters described above for internal 
Efficiency Analysis and the individual tests. 
Because the distributed data were previously 
Figure 1. Venn diagram showing populations N1 and N2, and the 
overlapping genes, N3.392
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normalized and ﬁ  ltered by the authors,
28 additional 
normalizations were not performed in assessing 
the tests. Results from the J5 family, fold-change 
family, t-test, and random feature selection were 
compared.
Naïve Bayes classiﬁ  cation
error estimation
Random Resampling Validation (RRV) was per-
formed on the Beer et al. dataset with the Naïve 
Bayes classiﬁ  er to produce internal cross-validation 
estimates of classiﬁ  er performance characteristics. 
As a preliminary assessment of the variation in 
performance associated with different normaliza-
tion methods, the D1 test was used in combination 
with transformation/normalization methods. 
The following parameters were used: Mean as a 
measure of central tendency, Naïve Bayes Classi-
ﬁ  er with the proportion of samples as the prior, 
100 iterations, a 70%–30% training/test split, and 
a threshold range of 0 to 50 with a 1.0 step. The 
Bhattacharjee dataset threshold ranged from 0 to 1 
with a step of  0.01. Unfortunately, tests that imple-
ment permutations (SAM and PPST) were not 
performed using RRV because caGEDA can not 
perform both resampling and randomization in 
stages simultaneously. Similar ranges and steps 
were used for the normalization methods, and a 
similar number of iterations were used in choosing 
the steps for the exceptions. The optimal threshold 
value was used for the classiﬁ  cation of the initial 
training/test set. The selected gene list, under the 
most efﬁ  cient normalization and test combination, 
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Figure 2. Efﬁ  ciency plot of statistical tests performed without normalization comparing the Beer and Bhattacharjee datasets. 
A) Over the entire gene range, and B) a gene range of 0–250. The J5 and D1 far outperform others based on amount of overlap. The above 
is a comparison of O (% overlap) vs. N3 (number of genes). The results are from overlap of the Beer and Bhattacharjee signiﬁ  cant gene 
lists. Abbreviations: N fold Ratio: Ratio of Mean; PVT: Pooled Variance t Test; RFS: Random Feature Selection.393
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was used to predict sample class labels using the 
Naïve Bayes Classiﬁ  er. Importantly, reciprocal 
external cross-validation was performed for each 
data set i.e. one dataset was used for training, and 
then tested on the other, and vice-versa.
Pace analysis
Additional computational validation was per-
formed using PACE Analysis.
33 Permutation 
Achieved Classiﬁ  cation Error (PACE) uses per-
mutations of the given data set to determine if the 
achieved classiﬁ  cation errors are signiﬁ  cant at the 
95% and 99% levels.
Intensity-related bias
As our study proceeded, we observed an apparent 
signal intensity-related bias of the J5 and derived 
tests toward the high end of the intensity range. 
Other tests appear to favor genes either at the low 
end, or in the mid-intensity range. To evaluate the 
impact of this problem, and the effects of other 
potential intensity-related biases, we rescaled each 
gene by the formula:
new_value = (old_value-min_value)/(max_
value-min_value) across all of the chips (within 
genes) and repeated Efﬁ  ciency Analysis on all 
methods.
J5 Test
The J5 test is a gene-speciﬁ  c ratio between the 
mean difference in expression intensity between 
two groups, A and B, to the average mean group 
difference of all M genes. The J5 is intended for 
use when t-tests are likely to exhibit unacceptably 
low speciﬁ  city (high false discovery rates) due to 
unstable estimates of the variance.
29 For a two-
group (A v B) comparison, the J5 test is described 
for the i
th of m genes as:
  J
m
i
ii
jj
j
m 5
1
1
=
−
−
− ∑
AB
AB
 (1)
Segmented J5
The Segmented J5 genes are ranked by median 
intensity and the entire distribution is divided into 
quantiles (default 100). We then used the mean 
parameter estimates from within each quantile 
separately, therefore eliminating the signal 
intensity bias. The mean of  the absolute value of 
the difference of means within a quantile is used 
for each gene as the J5 denominator for all genes 
in that quantile.
34
Intensity scaled J5
The Intensity Scaled J5 is similar to the segmented 
J5 but scaled using one of   the mean values 
(in case vs. control comparisons, the control 
comparison).
34
D1 Test
The D1 test is a twice-iterated J5 test where the 
remaining genes are tested after removing the ini-
tially discovered signiﬁ  cant genes during the ﬁ  rst 
iteration.
29
Results
Because we were most interested in relative efﬁ  -
ciency where N3M, we compared methods 
over a range N3 = 0–250 for all tests. Three sepa-
rate Efﬁ  ciency Analyses were performed for the 
lung adenocarcinoma data: 1) ‘BETWEEN’ data-
sets, 2) ‘BEER only’, and 3) ‘BHATTACHARJEE 
only’. Two classifications were performed: 
1) Beer—training/test with Bhattacharjee as a 
validation set, and 2) Bhattacharjee—training/test 
with Beer as the validation set.
Efﬁ  ciency analysis
Best test ‘BETWEEN’ the datasets
In this exercise we compared the genelists from 
Beer et al. and Bhattacharjee et al. Efﬁ  ciency 
Analysis was performed to determine the most 
consistent test. Under our criterion of efﬁ  ciency, 
the D1 and J5, appeared to produce similar 
results over a range of 1000 genes. While 
apparently far superior to the other tests as 
well as random feature selection (Fig. 2A, 
Appendix B1) within the 2500 gene range, the 
D1 and J5 were also superior in our range of 
interest (0–250) (Fig. 2B, Appendix B2). Further 
exploration of normalization was performed 
using the D1 test only.
Corrections for the intensity-related bias we 
observed did not inﬂ  uence the results greatly (for 
example, compare J5 to Segmented (Seg J5; 
Appendix B3). The results showed that the Intensity 394
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Scaled J5 seemed to be most consistent over the 
lower range of genes, 0–2000 genes. Other tests 
outperformed at higher values of  N3, but not until 
several thousands of genes were included (Appendix 
B1 and B3), however, the D1, J5, and Segmented 
J5 outperformed Random Feature Selection greatly, 
and appeared to be the most consistent test at a 
lower number of desired genes.
Most efﬁ  cient transformation/
normalization methods, both datasets
To study the effects of competing normalization 
effects on the efficiency of   the D1 test, we 
generated efﬁ  ciency curves for the D1 test under a 
variety of normalization methods. The locally 
optimized overlap at low N3 for the D1 test alone 
was 41.4% and occurred at 47 genes. Figure 3 
shows the results from the normalization com-
parisons. Although none of the normalization 
methods led to marked improvement, (Appendix 
B4 and B5), the quantile normalizations appeared 
to improve overlap results slightly over our gene 
range (0–100). Quantiles 25, 75, and 99 all per-
formed best at some point over the gene range. 
Therefore the “best” method of normalization 
depends on the number of genes in question. The 
Efficiency Analysis results from D1 alone 
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Figure 3. Efﬁ  ciency plot of normalization and transformation methods of the Beer and Bhattacharjee datasets. A) Over the entire 
gene range, and B) a gene range of 0–250. The D1 test was used with all methods. Again, the above results are from a comparison of O 
(% overlap) vs. N3 (number of genes). The results are from overlap of the Beer and Bhattacharjee signiﬁ  cant gene lists. A close look where 
N3m (Figure 2B) reveals that a few methods actually do minimally improve the efﬁ  ciency. Q: Quantile Normalization; TM: Trimmed Mean; 
GMA: Global Mean Adjustment; 5%–95%: Global Quantile Normalization utilizing the 5th–95th quantiles; SGM-Log2: The Subtract Global 
Minimum procedure was performed to eliminate negative values and allow for log transformation.395
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improved minimally using these normalizations 
(Fig. 3).
Most internally efﬁ  cient methods, 
BEER dataset
We split the Beer dataset randomly three times 
producing four independent, representative sample 
groups. Each group produced a gene list from the 
two populations (normal-cancer). As before, Efﬁ  -
ciency Analysis was performed to determine the 
most efﬁ  cient test. The D1, J5, and Segmented J5 
all appeared to give similar results over the speciﬁ  ed 
range of genes (0–250), while being far superior to 
the other tests as well as random feature selection 
(Fig. 4A, Appendix B6). To reduce the slight 
variation in performance associated with any arbi-
trary split, each of the most efﬁ  cient tests were 
re-analyzed 3-fold (Fig. 4B). Because the D1 test 
was evidently the most efﬁ  cient test for this data-
set (independent of intensity-scaling), further 
exploration of normalization was performed using 
the D1 test only.
As before, we wanted to assess the transformation/
normalization methods to see if, when used in 
combination with the D1 test, the percent overlap 
results would improve. The maximum overlap for 
the D1 test alone was 35% and occurred around 
0
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Figure 4. Efﬁ  ciency plot of statistical tests and the three most efﬁ  cient tests performed without normalization from the Beer dataset. 
A) A plot of several tests over the 0–250 gene range, and B) a plot of the three best performing tests over the same range. Certain tests 
appear to be more efﬁ  cient depending on the number of genes desired, but a few outperform all others over the given range. The above 
results are from a comparison of O (% overlap) vs. N3 (number of genes). The results are from overlap of the Beer signiﬁ  cant gene lists. 
It is apparent that the most efﬁ  cient test is the D1. D1 1, 2, and 3 are three iterations of the D1 test.396
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46 genes. The Z transform normalization method 
appeared to be most consistent over the entire range 
of genes (0–250). With Z transformation, the high-
est percent overlap occurred at 42 genes (Fig. 5, 
Appendix B7), with 21 of the genes being present 
on all lists 100% of the time (Appendix C, Table A). 
The normalization method increased O to almost 
46% (Fig. 5, Appendix B7).
Most internally efﬁ  cient methods, 
BHATTACHARJEE dataset
Again, Efﬁ  ciency Analysis was performed to 
determine the most consistent test. As before, 
the D1, J5, and Segmented J5 all appeared to 
give similar results over the speciﬁ  ed range of 
genes (0–125), while being superior to the other 
tests as well as random feature selection (Fig. 6, 
Appendix B8). Again, these three tests were 
re-analyzed at 3-fold (Fig. 6), with all three D1 
tests most efﬁ  cient. Next, the transformation/
normalization methods were tested. The maxi-
mum overlap for the D1 test alone was 28.7% 
and occurred around 101 genes (∼100 genes 
desired).
The results from the normalization comparisons 
are summarized as Figure 7, Appendix B9. The 
Trimmed mean 5%–95% normalization method 
outperformed all others over almost the entire 
range of genes (0–250). With TM 5%–95%, the 
highest percent overlap occurred at 102 genes, with 
32 of the genes being present on all lists 100% of 
the time (Appendix C, Table C). The normalization 
method increased the O to 29.2%.
Classiﬁ  cation
Classiﬁ  cation of the Beer dataset
Initial training using Beer dataset
The training and test error results using RRV (10 
resampling iterations) for the Beer dataset also 
indicated that D1 might be most useful. The D1 
(J5 family) test appeared to produce the lowest test 
Achieved Classiﬁ  cation Error (ACE) requiring 
only 4 genes, at a threshold of  31.0 (see Appendix D). 
The test ACE was ∼19% using the D1 alone (Fig. 8, 
Appendix B10) and improved to 18.4% with the 
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Figure 5. Efﬁ  ciency plot of normalization and transformation methods from the Beer dataset. The above results are from a comparison 
of O (% overlap) vs. N3 (number of genes). The results are from overlap of the Beer signiﬁ  cant gene lists. The D1 test was used with all 
available methods. It is apparent that the Z transformation appeared to produce the greatest overlap over most of the given range (0–250 genes), 
but others appeared optimal at the extreme low end.397
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Figure 6. Efﬁ  ciency plot of statistical tests and the three most efﬁ  cient tests performed without normalization from the 
Bhattacharjee dataset. A) A plot of several tests over the 0–250 gene range, and B) a plot of the three best performing tests over 
the same range. Certain tests appear to be more efﬁ  cient depending on the number of genes desired, but a few outperform all others 
over the given range. The above results are from a comparison of O (% overlap) vs. N3 (number of genes). The results are from 
overlap of the Bhattacharjee signiﬁ  cant gene lists. It is apparent that the most efﬁ  cient test is the D1. D1 1, 2, and 3 are three iterations 
of the D1 test.
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Figure 7. Efﬁ  ciency plot of normalization and transformation methods from the Bhattacharjee dataset. The above results are from 
a comparison of O (% overlap) vs. N3 (number of genes). The results are from overlap of the Bhattacharjee signiﬁ  cant gene lists. The D1 
test was used with all normalization methods. The Subtract Global Minimum procedure was performed to eliminate negative values and 
allow for log transformation. At 100 genes, TM 5%–95% appeared to be the best normalization method.398
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Quantile 99 normalization method (Fig. 9, 
Appendix B11). Importantly, both the test and the 
normalization methods were predicted to be most 
efficient! The threshold value with maximum 
overlap at N3N was used without RRV for 
classiﬁ  cation of individual samples for each test. 
The results were as follows: A between-mean array 
correlation after normalization of 0.984, the 
between array coefﬁ  cient of variation (COV) of 
0.034 before normalization, and 0.062 after 
normalization, and a confounding index 
(CI; compares the average within-group correlation 
to the average between-group correlation; The CI 
should be as close to 1.0 as possible, values higher 
than 1.0 may indicate incidental confounding in 
the experimental design
21) of 1.007 both before 
and after normalization. The combined score 
values from the four genes correctly classiﬁ  ed 
84.8% of the samples correct on average, with a 
sensitivity of 0.47 and a speciﬁ  city of 0.942. For 
the PACE Analysis, the D1 test with Quantile 99 
normalization and a threshold of 31 was used. 
100 iterations were performed over a threshold of 
0–15 with a step of 0.5. The ﬁ  ndings were not sig-
niﬁ  cant based on PACE Analysis (Appendix B14).
Bhattacharjee external validation dataset
The data from only the four genes (Appendix B15) 
of interest from the Beer dataset were retained from 
the Bhattacharjee dataset, and the classiﬁ  cation 
performed without normalization. The ACE, 
sensitivity, and specificity can be found in 
Appendix C, Table B. The best externally valid 
results were as follows: 79.7% of samples were 
classiﬁ  ed correctly, with a sensitivity of  0.352, and 
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Figure 8. Test ACE for tests using Beer dataset. As can be seen, the best ACE (19.4%) was found using the D1 test at around 3–4 genes. 
The second and third performers were also from the J5 family, which was consistent with Efﬁ  ciency Analysis results.
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Figure 9. RRV estimated test ACE under various normalization methods for the Beer dataset. The D1 test was performed with all 
transformation/normalization methods. Also consistent with Efﬁ  ciency Analysis is that the Quantile 99 method again produces the most 
efﬁ  cient results (18.45%) in combination with D1.399
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a speciﬁ  city of 0.942. Again, PACE Analysis was 
performed with the D1 test, Quantile 50 normaliza-
tion, over a range of 0–10 with a step of 0.5. PACE 
Analysis of the test set again appeared not to be 
signiﬁ  cant (Appendix B14). Xi et al.
35 examined 
the same datasets for classiﬁ  cation by lymph node 
status using PAM.
36 The Beer dataset was used for 
training, utilizing 318 genes, and Bhattacharjee 
was used as an external validation set, as we have 
done here. They reported test lymph node posi-
tive accuracy at 94.1%, but a lymph node 
negative accuracy of only 21.2%, and an overall 
test classification accuracy of 39.1% for the 
Bhattacharjee dataset.
Classiﬁ  cation of the Bhattacharjee dataset
The same methods and techniques were performed 
for cross-validation of the datasets.
Initial training using Bhattacharjee dataset
Random Resampling Validation (RRV) was 
performed on the Bhattacharjee et al. dataset 
with the same parameters as before. The results 
(test ACE) without and with normalization are 
shown in Figures 10 and 11, respectively. QC 
statistics were: between-mean array correlation 
after normalization of 0.996, the between array 
coefficient of variation (COV) of  0.028 before 
normalization, and 0.0030 after normalization, 
and a confounding index (CI) of 0.997 before 
and 0.998 after normalization. The lowest 
Achieved Classification Error (ACE) was 
32.0% (Fig. 10, Appendix B12), was achieved 
using the N fold Ratio test, with six retained 
genes, at a threshold of 0.37 (see Appendix C). 
This threshold was then used without RRV to 
classify individual samples. The combined score 
values from the six genes correctly classiﬁ  ed 
73.9% of the samples correctly, with a sensitiv-
ity of 0.235 and a speciﬁ  city of 0.903. For the 
PACE Analysis, the N fold ratio test with SGM-
Square Root normalization (Fig. 11, Appendix 
B13) and a threshold of 0.34 was used. 100 
iterations were performed over a threshold of 
0–10 with a step of 0.5. The PACE Analysis 
appeared to show ﬁ  ndings that are not signiﬁ  cant 
(Appendix B16).
Beer external validation dataset
The data from only the six returned genes 
(Appendix B17) from the Bhattacharjee dataset 
were removed from the Beer dataset, and the 
classification performed with all normalizations. 
The externally valid results were as follows: 
70.9% of samples were classified correctly, with 
a sensitivity of 0.411, and a specificity of 0.782. 
Again, PACE Analysis was performed with the 
N fold ratio test and SGM-Square Root normal-
ization (as well as SGM-Log 2, not shown), over 
a range of 0–8 with a step of 0.5. PACE Analysis 
of  the test set again seemed to show not signiﬁ  -
cant ﬁ  ndings (Appendix B16). Additionally, the 
D1 test was performed with and without normal-
ization and produced very similar results to the 
N fold ratio classiﬁ  cation. Xi et al.
35 reported the 
following ﬁ  ndings: a test lymph node classiﬁ  ca-
tion error of 70% for pathology-positive, and 38% 
for pathology-negative patients, and an overall 
cross-validated accuracy of 54%. Note that here 
the Bhattacharjee dataset was used for training, 
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Figure 10. Test ACE for tests using Bhattacharjee. As can be seen, the best ACE (30.7%) was found not using the D1 test, but the N fold 
ratio test. The J5 and D1 performed second and third best for this data set at 3–4 genes. This ﬁ  nding is not consistent with Efﬁ  cient 
Analysis.  400
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utilizing 318 genes, and Beer was used as an 
external validation set.
Discussion
Microarray technologies generate large volumes 
of potentially useful information and there have 
been many papers that have described tools and 
approaches for data analysis. Unfortunately the 
relative performance of the methods implemented, 
in the majority of available tools have not been 
compared extensively. We report on Efﬁ  ciency 
Analysis, which we envision could possibly be an 
early step in a standardizing procedure for micro-
array data analysis. The Efficiency Analysis 
described in this paper is based on the assumption 
that the most consistent test will provide the great-
est amount of overlap at a ﬁ  xed number of genes. 
We leave open the question of where the com-
parisons of the curves might be most meaningful, 
because this may depend entirely on the biology 
of a given study or investigation. An important 
advantage of this approach is that the identity of 
the genes are not examined in the comparison of 
different methods, thereby removing any possibility 
of imposing a biological bias in favoring one result 
over others.
Choe et al. (2005) used a control dataset to 
evaluate different methods. Their study was more 
focused on combinations of normalization/
transformation/tests for differential expression, but 
really only compared three tests for differential 
expression (t-test, Cyber T, and SAM).
37 We have 
shown that if the appropriate test is chosen ﬁ  rst, 
transformations/normalizations may alter the accu-
racy of the results but not substantially. The only 
real difference is that our method chooses and 
assesses the test ﬁ  rst, where Choe’s method follows 
a more classical progression of background 
correction to normalization to choosing the test 
last. By assessing the test at the beginning of the 
process, biases or other complications arising due 
to background subtraction, transformation/
normalization, and/or other variability may be 
avoided. Thus no “standard” method of data 
analysis currently exists and no approach has been 
described for determining the most efficient 
method for analysis of a given dataset.
The success of any research lies on reproduc-
ibility of results, as does Efﬁ  ciency Analysis. 
Dividing the dataset into additional variable groups 
a number of times had no signiﬁ  cant effect on the 
results obtained (data not shown), suggesting that 
the Efﬁ  ciency Analysis using the D1 test was 
robust. There is an issue of intensity-related bias 
in some tests for a certain number of genes, and 
this factor may impact Efﬁ  ciency Analysis. The 
Segmented J5 and Intensity Scaled J5 were created 
to further study, and may alleviate that problem 
(Appendix B3). By looking at the dataset over 
pre-assigned quantiles, the bias is addressed. The 
effects of this bias are evidently minimized by the 
Intensity Scaled J5 test (Appendix B3), and do not 
signiﬁ  cantly affect the results. The variation in 
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Figure 11. RRV estimated ACE scores for various normalizations. The N fold ratio test was performed with all transformation/normalization 
methods. The SGM-SqRt produced the most efﬁ  cient results in combination with N fold ratio (however not at the same N3 as before).  401
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performance among the different tests that we see 
has profound implications for studies that seek to 
determine whether a unique gene set might exist 
for a given clinical diagnosis, such as in breast 
cancer, and for metaanalysis.
38 Any metaanalysis 
of microarray data that simply uses the t-test, for 
example, without attempting to determine ﬁ  rst 
which of the scores of tests for ﬁ  nding differentially 
expressed genes might provide the highest true 
positive rate will be prone to ﬁ  nd vast differences 
among studies.
In this study, only single normalization methods 
were considered (no combinations). There very well 
may be a combination of transformation/
normalization methods that would produce better 
results than any of those tested in this study. Also, 
Naïve Bayes was the only classiﬁ  er tested in our study. 
It may be that other classiﬁ  ers will produce even better 
accuracy (e.g. PAM
36, SVM
39, CART
40, etc.)
The classiﬁ  cation results were considered taking 
a combination of performance characteristics and 
parameters into account (number of samples 
classiﬁ  ed correctly, sensitivity, speciﬁ  city, and 
number of genes). Classifying one test as the most 
consistent could vary depending on the parameter 
that is considered the most important. For our 
purposes, a minimal gene number, a low percent 
of classification error, high sensitivity and 
speciﬁ  city were all considered in deciding which 
methods produced the ‘most consistent’ classiﬁ  ca-
tion. We recognize that there are many biological 
factors (e.g. age, smoking history, weight, sex, diet, 
and environmental exposures), each of which could 
have inﬂ  uenced the performance of the test sig-
nificantly. We only stratified the cases into 
neoplastic and non-neoplastic groups, and did not 
take into consideration the potential effect of inﬂ  u-
ences such as those listed above, or the presence 
of other complex diseases. Also, there very well 
could be misclassiﬁ  cation of the samples involved, 
of which we are unaware.
There is disappointment that accompanies the 
classiﬁ  cation results not being signiﬁ  cant accord-
ing to PACE Analysis. Compared to other analyses 
using PAM
36 (i.e. Xi et al. 2005), who achieved 
impressive classiﬁ  cation errors (training accuracy 
of 88.4% when compared to pathology), we ﬁ  nd 
our RRV results reassuring in that they were pre-
dicted by Efﬁ  ciency Analysis. It may simply not 
be possible to differentiate normal lung tissue and 
adenocarcinoma tissue based solely on a few genes 
with the data and samples that were used. Xi et al. 
used a 318-gene set, with generally the same samples 
(15 omitted from the test set), to discriminate 
samples based on lymph node status and although 
the training errors were signiﬁ  cant, the overall test 
validation accuracy was 39.1% (Beer-train, 
Bhattacharjee-test) and a cross-validated 54% 
(Bhattacharjee-train, Beer-test). In our study, the 
ﬁ  nal classiﬁ  cations were the product of the test/
normalization combination that produced the 
lowest test classiﬁ  cation error for the existing 
methods. The several genes that appear to be con-
sistently differentially expressed may be of interest 
in lung adenocarcinoma. Three of the genes of 
interest appear to be closely related which will lead 
to further investigation. TFF3, CALCA, and 
PCSK1 all are listed by Bhattacharjee et al. as 
genes of interest in cluster C2 (an adenocarcinoma 
subclass). Of the remaining genes, only HLA-B 
appeared as being significant in other lung 
carcinoma papers investigated.
9,13,41,42
Sample and patient classiﬁ  cation is an important 
goal. We are encouraged by Efﬁ  ciency Analysis’ 
ability to somewhat determine the “best” performing 
test and normalization methods to use for 
classification in a way that is independent of 
generating the classiﬁ  cation, with the Beer dataset. 
For the Bhattacharjee dataset, N fold ratio pro-
duced the best classiﬁ  cation using RRV, but it is 
important to note that when D1 was independently 
used for classiﬁ  cation it produced very similar 
results. D1 and J5 ranked second and third. When 
compared to the Beer dataset, the Bhattacharjee 
dataset appeared to be ‘less consistent’. This may 
be due to experimental or biological effects, but 
we cannot say for certain. Obviously further inves-
tigation is required. External Efﬁ  ciency Analysis 
is available through the Overlap4 tool, and internal 
Efﬁ  ciency Analysis is automated in caGEDA under 
“Computational Validation” options. We invite 
others to participate in using caGEDA and Efﬁ  -
ciency Analysis using their own datasets.
During the preparation of this manuscript, the Rat 
toxicogenomic MAQC study was released in Nature 
Biotechnology.
28 Guo et al. assessed the concor-
dance in inter-site and cross-platform comparisons 
and the impact of gene selection methods on the 
reproducibility of proﬁ  ling data in terms of differ-
entially expressed genes.
28 In order to validate their 
ﬁ  ndings, the authors used percent overlap of gene 
lists, between different laboratories and/or platforms, 
as their evaluation method. They concluded the same 
as we did (prior to reading their report) that, gene 402
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lists generated by fold-change were more 
reproducible than those obtained by t-test or 
SAM.
28 Additionally, conclusions reported by Guo 
et al. further support our claims as well: 1) Criteria 
used to deﬁ  ne differentially expressed genes can 
have a dramatic impact on the overlap of the 
resulting genelists, 2) Findings are reproducible 
across laboratories and platforms when the pre-
ferred gene selection criteria are used, 3) Normal-
ization methods do not alter the gene lists unless 
a p-value criterion is involved in gene selection, 
4) Fold-change performed the best, followed by 
SAM and lastly the t-test (with mention of the 
problems with gene selection methods based solely 
on t-test p-values), 5) The importance of appropri-
ate data analysis procedure as a whole (and may 
we add the order).
28
Efﬁ  ciency analysis was performed on the Rat 
toxicogenomic study data, the results of which can 
be seen in Appendix E. In support of our previous 
conclusions, the J5 performed best overall, better 
than fold-change, and the t-test performed poorly 
in almost all situations. We believe that including 
an analysis of the MAQC Rat toxicogenomic data 
should clarify some doubt as to whether Efﬁ  ciency 
Analysis’ has ability to predict the ‘best test’. 
Although the results were minimally platform-
dependent, we believe that our previous assertions 
are further supported by these results. We extend 
their ﬁ  ndings and add that under a similar criterion, 
the J5 was more reproducible than fold change.
Our interpretation of the results must be stated 
with important caveats. Absent independent valida-
tion, for example, by RT-PCR, it may be premature 
to conclude the relative order of the reproducibility 
and consistency of the methods explored.
In conclusion, Efﬁ  ciency Analysis appears to 
distinguish among tests that are incapable of pro-
viding consistent results and seems to also be able 
to generally predict which feature selection 
methods yield the lowest sample classiﬁ  cation 
error. Although not always correct, the method does 
produce, if not the ‘best’ test, a general understanding 
of which tests yield similar internally and exter-
nally consistent results. We were surprised by the 
consistently poor performance of the t-test and 
variants of that test. We urge caution in the use of 
estimates of variance derived from small sample 
sets in high dimensions, and ﬁ  nding differentially 
expressed genes in solid tumors using tests derived 
from second central moment estimates.
30 Note the 
J5 and related tests avoid the use of estimated 
variance altogether. The D1 test gave the highest 
percent overlap in both datasets, and although 
the results were validated by independent datasets, 
the features selected did not lead to a signiﬁ  cant 
Naïve Bayes classiﬁ  er, but then neither did most 
other gene lists from other tests. This may be due 
to intrinsic molecular heterogeneity within lung 
cancer; the Naïve Bayes model, like other ﬁ  xed-
marker intensity input additive linear models, uses 
all genes for all patients. Research is needed on 
classiﬁ  ers that are robust to the intrinsic molecular 
heterogeneity of cancers.
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Appendix A
The following descriptions taken from the caGEDA 
website:
Threshold-based tests
J5: compares the difference of means in any gene 
to the average difference in means over the 
whole array.
D1: performs the J5 once, removes all signiﬁ  -
cant genes, and performs the J5 again to capture 
any genes that were missed initially.
Signal-to-Noise: similar to t test with a high 
positive false discovery rate.
Segmented J5: developed out of concern over 
intensity-related bias in the tests. The segmented 
J5 was designed to determine whether the J5 test 
was more efﬁ  cient than the other tests when the 
denominator was calculated only using genes with 
similar intensity. In the segmented J5, genes are 
ranked by median intensity and a number of quan-
tiles are determined. The mean of the absolute 
value of the difference of means is used for each 
gene within a quantile as the J5 denominator.
Intensity Scaled J5: similar to segmented J5 but 
scaled using the entire range of intensities.
Normalization methods
Within-array
Sum: all intensity values on the array are multiplied 
by the sum of all intensity values on the array.
Mean: all intensity values on the array are 
multiplied by the mean of all intensity values on 
the array.
Median: all intensity values on the array are 
multiplied by the median of all intensity values on 
the array.
Quantile/Percentile: all intensity values on 
the array are multiplied by the mean of all inten-
sity values on the array beyond the speciﬁ  ed 
quantile.
Trimmed mean: all intensity values on the array 
are multiplied by the mean of all intensity values 
on the array between two speciﬁ  ed quantiles.
Among-array
Median mean: the mean intensity of each array is 
calculated, the median mean is identiﬁ  ed, and an 
array-speciﬁ  c multiplicative factor is deﬁ  ned as 
the ratio of that array’s mean to the median mean
Minimum mean: same as median mean but 
instead of normalizing to the median mean, the 
scaling factor is the minimum mean of all of the 
arrays.
Global mean adjustment: the global mean inten-
sities of all arrays are calculated, then the differ-
ence between each individual array mean and the 
global mean is calculated, the array-speciﬁ  c dif-
ference value is then added to or subtracted from 
each individual expression intensity value on an 
array and the result is that all arrays now have the 
same overall mean.
Max1, Min0: re-scales each expression intensity 
proﬁ  le so the array-speciﬁ  c maxima and minima 
are equal in all arrays.
Z-transformation: similar to log transformation 
in that it can change the shape of the distribution, 
but can reduce performance of some tests for dif-
ferentially expressed genes.405
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Appendix B
Appendix B1. Efﬁ  ciency plot of statistical tests performed without normalization. The entire gene range is shown. The J5 and D1 
far outperform others based on amount of overlap. The above is a comparison of O (% overlap) vs. N3 (number of genes). The results are 
from overlap of the Beer and Bhattacharjee signiﬁ  cant gene lists. Abbreviations are as follows: BSS-WSS: Between Sum of Squares, 
Within Sum of Squares; IntSc J5: Intensity Scaled J5; N fold: [(M1-M2)/M2]; N fold Ratio 1: Ratio of Mean; PPST: Permutation Percentile 
Separability; PVT: Pooled Variance t Test; RFS: Random Feature Selection; SAM: Signiﬁ  cance Analysis of Microarray; SegJ5: Segmented 
J5; SST: Simple Separability Test; SN: Signal to Noise Ratio; WL: Wilks Lambda Test.
Appendix B2. Efﬁ  ciency plot of statistical tests performed without normalization. A gene range of 0–250 is shown. The J5 and D1 
far outperform others based on amount of overlap. The above is a comparison of O (% overlap) vs. N3 (number of genes). The results are 
from overlap of the Beer and Bhattacharjee signiﬁ  cant gene lists. Abbreviations are as follows: BSS-WSS: Between Sum of Squares, 
Within Sum of Squares; IntSc J5: Intensity Scaled J5; N fold: [(M1-M2)/M2]; N fold Ratio 1: Ratio of Mean; PPST: Permutation Percentile 
Separability; PVT: Pooled Variance t Test; RFS: Random Feature Selection; SAM: Signiﬁ  cance Analysis of Microarray; SegJ5: Segmented 
J5; SST: Simple Separability Test; SN: Signal to Noise Ratio; WL: Wilks Lambda Test.406
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Appendix B3. ‘Pre-normalized’ plots from within gene corrected data. The Intensity Scaled J5 is superior at lower number of genes. 
The reduction in efﬁ  ciency in many tests provides evidence that the apparent bias does exist for those methods, but their relative ranking 
does not alter signiﬁ  cantly the interpretation of the results.
Appendix B4. Efﬁ  ciency plot of transformation/normalization methods. The 0–100 gene range, comparing the Beer and Bhattacharjee 
datasets, is shown. Based on this ﬁ  gure alone it doesn’t appear that any normalization method improves the D1 efﬁ  ciency. However, a closer 
look where N3<<m (Figure 2) reveals that a few methods actually do improve efﬁ  ciency.  407
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Appendix B5. Efﬁ  ciency plot of normalization and transformation methods. The D1 test was used with all methods. Again, the above 
results are from a comparison of O (% overlap) vs. N3 (number of genes). The results are from overlap of the Beer and Bhattacharjee 
signiﬁ  cant gene lists. Q: Quantile Normalization utilizing quantiles; TM: Trimmed Mean utilizing quantiles; GMA: Global Mean Adjustment; 
5%–95%: Global Quantile Normalization utilizing the 5th–95th quantiles; SGM-CondLog: Subtract Global Minimum, Conditional Log 
Transformation. The Subtract Global Minimum procedure was performed to eliminate negative values and allow for log and square root.
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Appendix B6 . Efﬁ  ciency plot of statistical tests performed without normalization for the Beer dataset. Only the 0–150 gene range 
is shown. Certain tests appear to be more consistent depending on the number of genes desired, but a few outperform all others over the 
given range. The above results are from a comparison of O (% overlap) vs. N3 (number of genes). The results are from overlap of the Beer 
signiﬁ  cant gene lists. O is percent overlap; N3 is the number of genes.    408
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Appendix B7. Efﬁ  ciency plot of normalization and transformation methods for the Beer dataset. The above results are from a 
comparison of O (% overlap) vs. N3 (number of genes). The results are from overlap of the Beer signiﬁ  cant gene lists. The D1 test was used 
with all available methods. It is apparent that the Z transformation appeared to produce the greatest overlap over most of the given range 
(0–125 genes), but others appeared optimal at the extreme low end.
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Appendix B8. Efﬁ  ciency plot of statistical tests performed without normalization for the Bhattacharjee dataset. The above results 
are from a comparison of O (% overlap) vs. N3 (number of genes). The results are from overlap of the Bhattacharjee signiﬁ  cant gene lists.   
Only the 0–125-gene range is shown. The J5 family of tests appeared to be most efﬁ  cient.    409
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Appendix B9. Efﬁ  ciency plot of normalization and transformation methods for the Bhattacharjee dataset. The above results are from 
a comparison of O (% overlap) vs. N3 (number of genes). The results are from overlap of the Bhattacharjee signiﬁ  cant gene lists. The D1 
test was used with all normalization methods. The Subtract Global Minimum procedure was performed to eliminate negative values and 
allow for log and square root transformations. At 100 genes, TM 5%–95% was the best normalization method.
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Appendix B10. Test ACE for tests using Beer dataset. As can be seen, the best ACE (19.4%) was found using the D1 test at around 
3–4 genes. The second and third performers were also from the J5 family, which was consistent with Efﬁ  ciency Analysis results.410
Jordan et al
Cancer Informatics 2008:6 
15
20
25
02468 1 0 N3
A
C
E
No Norm
SGM Log2
SGM CondLog
SGM SqRt
Sum
Mean
Median
Q25
Q50
Q75
Q90
Q95
Q99
TM 25-75
TM 10-90
TM 5-95
TM 1-99
Min Mean
Med Mean
GMA
Max1 Min0
Z transform
5%-95% Adjust
Appendix B11. RRV estimated ACE under various normalization methods. The D1 test was performed with all transformation/normalization 
methods. Also consistent with Efﬁ  ciency Analysis is that the Quantile 99 method again produces the most efﬁ  cient results (18.45%) in 
combination with D1.
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Appendix B12. Test ACE for tests using Bhattacharjee. As can be seen, the best ACE (30.7%) was found not using the D1 test, but the 
N fold ratio test. The J5 and D1 performed second and third best for this data set at 3–4 genes. This ﬁ  nding is not consistent with Efﬁ  cient 
Analysis.  411
Differentially expressed genes in lung adenocarcinoma
Cancer Informatics 2008:6
Appendix B13. RRV estimated ACE scores for various normalizations from the Bhattacharjee dataset. The N fold ratio test was 
performed with all transformation/normalization methods.
Appendix B14. Training set Random Resampling Validation and PACE plots. The lowest classiﬁ  cation error, for the Beer dataset, was 
18.4% at a threshold of 31.0, requiring only 4 genes on average. PACE Analysis showed that the ﬁ  ndings did not appear to be signiﬁ  cant. 
This is made apparent by the red line (black beaded line) never intersecting the blue 95% line. 
Appendix B15. Score histogram and Expression Grid plot of signiﬁ  cant genes found using the D1 score at a threshold of 31.0. 
Results are from the Beer dataset. The score histogram shows the gene regulation based on the test score, the expression pattern grid is 
a heat map of expression values over each sample, separated by class.  412
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Appendix B16. Training set Random Resampling Validation and PACE plots. The best achieved classiﬁ  cation error, for the Bhattacharjee 
dataset, was 32.0% at a threshold of 0.37, requiring ﬁ  ve genes. The PACE Analysis shows that the ﬁ  ndings did not seem signiﬁ  cant.This is 
made apparent by the red line (thick black line) never falling below the blue 95% line.
Appendix B17. Score histogram and Expression Grid plot of signiﬁ  cant genes found using the N fold Ratio score at a threshold 
of 0.37. Results are from the Bhattacharjee dataset.413
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Table B. Bhattacharjee dataset used for external validation of the beer dataset classiﬁ  er.
Norm method % Correct Sensitivity Speciﬁ  city Between-mean 
array correlation 
(after 
normalization)
Between array 
coefﬁ  cient of 
variation (after 
normalization)
Confounding 
index (after 
normaliza-
tion)
Quantile 50 0.797 0.352 0.942 0.993 0.207 0.994
SGM-Log2 0.782 0.176 0.98 0.999 0.069 0.998
Max1, Min0 0.768 0.058 1 0.998 0.126 0.994
SGM-Square 
Root Trans
0.768 0.058 1 0.999 −1.103 0.999
5%–95% 
Adjust
0.753 0 1 0.998 0.173 0.994
SGM-Cond 
Log Trans
0.753 0.058 0.98 0.999 0.38 1
Global Mean 
Adjust
0.753 0 1 0.999 0 0.994
Mean 0.753 0.117 0.961 0.997 0 0.994
Minimum 
Mean
0.753 0.117 0.961 0.997 0 0.994
Quantile 25 0.753 0.117 0.961 0.997 0.398 0.994
Quantile 75 0.753 0.117 0.961 0.998 0.154 0.994
Quantile 90 0.753 0.117 0.961 0.998 0.154 0.994
Quantile 95 0.753 0.117 0.961 0.998 0.154 0.994
Quantile 99 0.753 0.117 0.961 0.998 0.154 0.994
Sum 0.753 0.117 0.961 0.997 0 0.994
Median 0.739 0.117 0.942 0.994 0.178 0.994
Median Mean 0.739 0.058 0.961 0.999 0.503 0.994
No Norm 0.739 0 0.98 0.999 0.246 0.994
Trimmed 
Mean 10–90
0.739 0.235 0.903 0.994 0.218 0.994
Trimmed 
Mean 1–99
0.739 0.235 0.903 0.994 0.218 0.994
Trimmed 
Mean 25–75
0.739 0.117 0.942 0.994 0.178 0.994
Trimmed 
Mean 5–95
0.739 0.235 0.903 0.994 0.218 0.994
Z Trans 0.724 0 0.961 0.998 −15.474 0.994417
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Table C. Beer dataset used for external validation of the Bhattacharjee dataset classiﬁ  er.
Norm Method % Correct Sensitivity Speciﬁ  city Between-mean 
array correlation 
(after normaliza-
tion)
Between array 
coefﬁ  cient of 
variation (after 
normalization)
Confounding 
index (after 
normalization)
SGM-Log2 0.709 0.411 0.782 0.931 0.105 0.985
Quantile 75 0.511 0.647 0.478 0.996 0.807 0.989
Mean 0.488 0.705 0.434 0.993 0 0.989
Minimum Mean 0.488 0.705 0.434 0.993 0 0.989
Sum 0.488 0.705 0.434 0.993 0 0.989
Z Trans 0.476 0.647 0.434 0.992 −30.447 0.989
5%–95% Adjust 0.465 0.882 0.362 0.991 0.252 0.989
Global Mean 
Adjust
0.465 0.705 0.405 0.902 0 0.989
Max1, Min0 0.465 0.882 0.362 0.991 0.258 0.989
Quantile 90 0.465 0.647 0.42 0.991 0.265 0.989
Quantile 95 0.465 0.647 0.42 0.991 0.265 0.989
Quantile 99 0.465 0.647 0.42 0.991 0.265 0.989
SGM-Square 
Root Trans
0.441 0.941 0.318 0.961 0.372 0.988
No Norm 0.43 1 0.289 0.902 0.862 0.989
Trimmed Mean 
10–90
0.418 0.764 0.333 0.987 0.767 0.989
Trimmed Mean 
1–99
0.418 0.764 0.333 0.987 0.767 0.989
Trimmed Mean 
5–95
0.418 0.764 0.333 0.987 0.767 0.989
Median Mean 0.406 1 0.26 0.557 2.067 0.989
Quantile 25 0.406 1 0.26 −0.721 −10.2 1.018
SGM-Cond Log 
Trans
0.36 1 0.202 0.966 0.886 1.026
Quantile 50 0.36 0.941 0.217 0.622 2.417 0.989
Trimmed Mean 
25–75
0.36 0.941 0.217 0.768 1.915 0.989
Median 0.348 0.941 0.202 0.694 2.2 0.989418
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Appendix D
Genes of interest
The genes and descriptions are described below. 
The information was taken from The NCBI Entrez 
nucleotide database (http://www.ncbi.nlm.nih.
gov/entrez) using the corresponding 
GenBank ID’s.
RPLP1 (NM_001003, Ribosomal protein, 
large, P1, transcript variant 1). (AKA: P1, RPP1, 
FLJ27448).
This gene encodes a ribosomal phosphoprotein 
that is a component of the 60S subunit and 
is located in the cytoplasm. It plays an important 
role in the elongation step of protein synthesis. The 
encoded protein is acidic, and its functions include 
RNA binding and being a structural constituent of 
ribosome. RPLP1 is involved in the protein bio-
synthesis and translational elongation processes.
RPL37 (NM_000997, Ribosomal protein L37) 
(AKA: MCG99572). 
This gene encodes a ribosomal protein that is a 
component of the 60S subunit, and is located in 
the cytoplasm. The protein contains a C2C2-type 
zinc ﬁ  nger-like motif.
COL1A1 (NM_000088, Collagen, type I, 
alpha 1) (AKA: OI4). 
This gene encodes the major component of type 
I collagen, found in most connective tissues, and 
the only component of the collagen found in car-
tilage. Translocations in this region may result in 
unregulated expression of growth factor.
HLA-B (NM_005514, Major histocompatibility 
complex, class I, B).
This class I molecule is a heterodimer (beta-2 
microglobulin). Class I molecules play a central 
role in the immune system by presenting 
peptides derived from the ER lumen. Class 
I molecules are expressed in nearly all cells. 
Polymorphisms within this gene are responsible 
for the peptide binding speciﬁ  city of each Class 
I molecule. HLA-B is integral to plasma 
membrane, and functions as a Class I receptor. 
HLA-B is involved in antigen processing and 
presentation in the immune response. HLA-B, 
(MHC class 1, B receptor) was found in the Beer 
et al. paper as one of the top 100 survival-related 
genes from cross-validation, found to be signiﬁ  -
cantly (p = 0.000391) downregulated in Stage 3 
vs. Stage 1 by 40%, but not signiﬁ  cantly different 
in normal vs. tumor.
PCSK1 (NM_000439, Proprotein convertase 
subtilisin/kexin type 1) (AKA: PC1, PC3, NEC1, 
SPC3).
Proprotein convertases process precursor pro-
teins into their biologically active products. PCSK1 
is a Type I proinsulin-processing enzyme that plays 
a role in regulating insulin biosynthesis. Mutations 
in this gene are thought to contribute to obesity, 
and this protein has also been associated with car-
cinoid tumors. PCSK1 is listed on the marker gene 
list by Bhattacharjee as a member of their C2 
cluster subclass.
TFF3 (NM_003226, Trefoil factor 3 (intestinal)) 
(AKA: ITF, TFI, HITF).
Members of the trefoil family are secretory 
proteins expressed in intestinal mucosa. They may 
protect the mucosa from insults, stabilize the 
mucus layer and affect healing of the epithelium. 
This gene is expressed in goblet cells of the intes-
tines and colon. TFF3 is listed on the marker gene 
list by Bhattacharjee twice as a member of the C2 
cluster subclass.
CALCA (NM_001741, Calcitonin/calcitonin-
related polypeptide, alpha). (AKA: CT, KC, CGRP, 
CALC1, CGRP1, CGRP-I).
Calcitonin is a peptide hormone synthesized by 
the thyroid. CALCA is also listed twice on the 
marker gene list by Bhattacharjee as a member of 
the C2 cluster subclass.
CYP2B (NM_000767, Cytochrome P450, 
family 2, subfamily B, polypeptide 6) (AKA: 
CPB6, IIB1, P450, CYP2B6, CYPIIB6).
CYP2B, catalyzes many reactions involved in 
drug metabolism and synthesis of cholesterol, 
steroids and other lipids. This protein is localized 
to the ER and is known to metabolize some xeno-
biotics, such as anti-cancer drugs.
IFI27 (NM_005532, Interferon, alpha-induc-
ible protein 27, transcript variant a) (AKA: P27, 
ISG12).
UGB (NM_003357, Secretoglobin, family 1A, 
member 1 (uteroglobin)). (AKA: SCGB1A1, 
CC10, CC16, CCSP)).419
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Appendix E1. Efﬁ  ciency plot of kidney data from the Rat toxicogenomic study. A) ABI C-AA, B) Agilent C-AA, C) Affymetrix C-AA, D) 
GE C-AA. The J5 appears to perform the best over all platforms used. Dark blue: J5; pink: simple t-test; yellow: nfold1; turquoise: nfold2; 
purple: nfold3; black: random feature selection. AA = Aristolochic acid.420
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Appendix E2. Efﬁ  ciency plot of liver data from the Rat toxicogenomic study. A) ABI C-AA, B) Agilent C-AA, C) Affymetrix C-AA, D) 
GE C-AA. The J5 appears to perform quite well compared to the other methods. Dark blue: J5; pink: simple t-test; yellow: nfold1; turquoise: 
nfold2; purple: nfold3; black: random feature selection. AA = Aristolochic acid.
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Appendix E3. Efﬁ  ciency plot of liver data from the Rat toxicogenomic study. A) ABI C-C, B) Agilent C-C, C) Affymetrix C-C, D) GE C-C. 
The J5 appears to again perform quite well compared to the other methods. Dark blue: J5; pink: simple t-test; yellow: nfold1; turquoise: nfold2; 
purple: nfold3; black: random feature selection. C-C = Comfrey roots.421
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Appendix E4. Efﬁ  ciency plot of liver data from the Rat toxicogenomic study. A) ABI C-R, B) Agilent C-R, C) Affymetrix C-R, D) GE C-R. 
The J5 appears to perform the best in 3 out of 4 platforms (only being outperformed by nfold1 on the Affymetrix platform). Dark blue: J5; pink: 
simple t-test; yellow: nfold1; turquoise: nfold2; purple: nfold3; black: random feature selection. C-R = Comfrey Roots/Riddelliine.